1. Home
  2. FTFT vs LEXX Comparison

FTFT vs LEXX Comparison

Compare FTFT & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Future FinTech Group Inc.

FTFT

Future FinTech Group Inc.

HOLD

Current Price

$1.06

Market Cap

22.0M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.85

Market Cap

22.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTFT
LEXX
Founded
N/A
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.0M
22.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FTFT
LEXX
Price
$1.06
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
109.0K
167.8K
Earning Date
11-14-2025
01-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,665,719.00
$705,923.00
Revenue This Year
N/A
$13.35
Revenue Next Year
N/A
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$1.01
$0.77
52 Week High
$5.00
$2.43

Technical Indicators

Market Signals
Indicator
FTFT
LEXX
Relative Strength Index (RSI) 32.66 37.66
Support Level $0.95 $0.82
Resistance Level $1.32 $1.44
Average True Range (ATR) 0.11 0.10
MACD 0.01 -0.02
Stochastic Oscillator 12.56 4.67

Price Performance

Historical Comparison
FTFT
LEXX

About FTFT Future FinTech Group Inc.

Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

Share on Social Networks: